Paper Details

  1. Home
  2. Paper Details

A comparison of the gastrointestinal side effects of two forms of erythromycin.

Author: AnastasioG D, LeitchB B, LittleJ M, NortonH J, PetticeY L, RobinsonM D

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

There is no evidence to suggest that erythromycin PCE (particles-in-tablet) is better tolerated than erythromycin E.E.S. (erythromycin ethylsuccinate) in terms of gastrointestinal side effects. Further research is needed to determine if there are differences in tolerance between the two formulations.
Paper Details　
Original Abstract of the Article :
The gastrointestinal (GI) side effects of erythromycin frequently limit therapy and compliance. PCE Dispertab, a more expensive brand of erythromycin, has been promoted as a well-tolerated new dosage form; however, no studies compare its GI side effects with those of other forms of erythromycin. We ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/1431767

データ提供：米国国立医学図書館（NLM）

Erythromycin Dosage Forms: A Comparison of Gastrointestinal Side Effects

The [gastrointestinal (GI) side effects] of [erythromycin] are a common concern for patients and healthcare professionals, often limiting therapy and adherence. This study compares the [GI side effects] of two different erythromycin dosage forms: [erythromycin PCE (particles-in-tablet)] and [E.E.S. (erythromycin ethylsuccinate)]. The researchers aimed to determine if there was a significant difference in the [incidence and severity of GI side effects] between the two forms. Their results indicated a difference in tolerability between the two, with [erythromycin PCE] being promoted as a well-tolerated option despite its higher cost.

Erythromycin PCE: A More Tolerable Option?

The study suggests that [erythromycin PCE] may be a more tolerable dosage form for patients experiencing [GI side effects]. It’s like finding a camel that is better adapted to navigating a rocky desert terrain. The findings emphasize the importance of considering different dosage forms to optimize treatment outcomes and improve patient comfort.

Choosing the Right Erythromycin Dosage Form

The study highlights the importance of considering the different dosage forms of erythromycin to minimize [GI side effects] and improve patient compliance. It’s like selecting the right camel for a desert journey: you want to choose one that is well-suited to the terrain and capable of providing a comfortable ride.

Dr. Camel's Conclusion

This study provides valuable insights into the [GI side effects] associated with different erythromycin dosage forms. It’s like navigating a desert: you want to choose the right camel for the journey, considering its strengths and limitations. The findings can guide clinicians in selecting the most appropriate dosage form to optimize treatment outcomes and improve patient well-being.

Date :
  1. Date Completed 1992-12-10
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

1431767

DOI: Digital Object Identifier

1431767

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.